Citation: Shaeen S, Sattar NA, Ibrahim M and Irfan M. Role of Remdesivir in COVID-19. Austin J Pulm Respir Med. 2021; 8(1): 1071. Austin J Pulm Respir Med - Volume 8 Issue 1 - 2021 ISSN : 2381-9022 | www.austinpublishinggroup.com Sattar et al. © All rights are reserved Austin Journal of Pulmonary & Respiratory Medicine Open Access Abstract Remdesivir is an antiviral drug showed broad spectrum against viruses, also RNA polymerase inhibitor that’s why use to treat a variety of RNA virus infections. It is considered to be more effective against family of respiratory infection causing viruses including corona virus as compared to those whom it was originally synthesized like Hepatitis C and common cold viruses. On October 8, 2020, The National Institute of Allergy and Infectious Diseases has completed trials on COVID-19 patients and found Remdesivir satisfactory and benefciary choice towards the recovery stairs of COVID-19. The pandemic of Covid-19 might wean down by season, but the possibility of reoccurrence exists. Thus, future clearance of Remdesivir might be critical for ensuring effective treatment, diminish mortality and permit early release. Introduction Promising and reemerging pathogens are global challenges for public health [1], while various curative agents have been investigated for the cure against them. Among these pathogens especially viruses the coronavirus is considered to be more threatening and changeable to the world in recent times. Tere are almost six diferent classes of coronavirus which are well recognized to causing human disease [2]. Coronaviruses are consisting on ribonucleic acid envelope which circulated generally in not only humans but other mammals and amphibians. In among them this novel virus causes various hepatic and neurologic problems with severe respiratory tract infection [3,4]. Among these six classes of corona four are i.e. HKU1, 229E, OC43 and NL63 widespread to cause symptoms of infuenza in immune- compromising people [4], while remaining two other strains (SARS- CoV, MERS-CoV) are responsible to causing intense symptoms of respiratory tract infections lead to fatal illness [5]. Epidemiology of COVID-19 Currently, the pandemic of COVID-19 belong to virus family Coronaviridae causing pulmonary infection in humans of known as fatal acute pulmonary syndrome SARS-CoV-2. In 2019, the disease of coronavirus is epidemic that starts in late 2019, has spread as global pandemic and in various populations is commonly susceptible to disease with great rate of contagiousness [5], which still ongoing day by day (Figure 1). In April of 2020, the reported cases of this pandemic coronavirus have amplifed dozens of times i.e. 4692797, with the increasing number of afected countries [6,7]. Almost 50% cases of Coronavirus in late 2019 need negligibly mechanical ventilation but on a regular basis have need of hospitalization. Te over saturation in medicinal facilities, especially concern units are insidious in various subjective nations. Development of Effective Drug/Vaccine Tus, it has been most and urged task for the feld of research and development of the drug since the outbreak of COVID-19 to develop efective and suitable drugs for the treatment and vaccines for prevention of coronavirus. About 79.5% similarities at nucleic acid level have been discovered between COVID-19 and SARS- Review Article Role of Remdesivir in COVID-19 Sumera Shaeen 1 , Naila Abdul Sattar 1 *, Mohammad Ibrahim 2 and Muhammad Irfan 2 1 Department of Biochemistry, Government College Women University, Faisalabad 2 Department of Pharmaceutics, Government College University, Faisalabad *Corresponding author: Naila Abdul Sattar, Department of Biochemistry, Government College Women University, Faisalabad Received: April 08, 2021; Accepted: April 27, 2021; Published: May 04, 2021 CoV through molecular analysis while 94.6% similar index found in amino acids makeup of seven diferent preserved proteins having nonstructural properties [8,9]. Te ICTV (international committee on taxonomy of viruses) discovered new COVID-19 related to the fatal acute respiratory syndrome belongs to this species and named it coronavirus 2 or SARS-CoV-2 which show symptoms; dyspnoea, fever, cough and difculty of breath [10-12] that lead to pneumonia or even death because multiple organ failure [13-16]. At present, no any kind of most appropriate drug has been develop but globally only few developed countries get partial success to market antibody/ vaccine (monoclonal) for the impediment of SARS-CoV-2 diseases [17,18] while medical practitioners are taking into consideration to repurposing diferent approved drugs to cure the infections of coronavirus [19-26]. Remdesivir (GS-5374) Among several approved drugs against viral infections the remdesivir is considered to be frst line of choice for COVID-19 infections. Remdesivir is a monophosphoramidate pro-drug of adenosine analogue, which is viable inhibitor of ribonucleic acid polymerase belong COVID-19, administered as a “considerate medication” in the empathetic drug principle utilize yet though and not met the circumstances for sanction [27-29]. Current review article describes the recent grade, patents, procedure, pre-clinical study and trial development of remdesivir. Even if the existing data is not enough to make clear the action of remdesivir against COVID-19, the consequences revealed that the antiviral action of this drug against new other species of COVID-19 have provided researchers adequate assurance which resulted in elevated prospect. Te clinical Studies on the utilization of remdesivir for the cure of coronavirus are still continuing [17]. History of Remdesivir It is an antitoxin drug produced by Biopharmaceutical Gilead, USA. Biochemically remdesivir is a simple nucleotide i.e. adenosine that entrenched into the ribinulceic acid chain of virus and responsible of its end untimely. It is being concerted in the year 2020 as an alternative curing agent afer coronavirus disease [1]. Biopharmaceutical referred a laboratory deriver prelude against